Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Amortization of Deferred Charges (2019 - 2023)

Harmony Biosciences Holdings' Amortization of Deferred Charges history spans 5 years, with the latest figure at $424000.0 for Q2 2023.

  • For Q2 2023, Amortization of Deferred Charges rose 3.16% year-over-year to $424000.0; the TTM value through Jun 2023 reached $1.7 million, down 1.18%, while the annual FY2022 figure was $1.7 million, 25.69% down from the prior year.
  • Amortization of Deferred Charges for Q2 2023 was $424000.0 at Harmony Biosciences Holdings, up from $416000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q4 2020 and bottomed at -$901000.0 in Q4 2019.
  • The 5-year median for Amortization of Deferred Charges is $418000.0 (2021), against an average of $416800.0.
  • The largest annual shift saw Amortization of Deferred Charges soared 254.5% in 2020 before it crashed 69.97% in 2021.
  • A 5-year view of Amortization of Deferred Charges shows it stood at -$901000.0 in 2019, then skyrocketed by 254.5% to $1.4 million in 2020, then plummeted by 69.97% to $418000.0 in 2021, then increased by 0.96% to $422000.0 in 2022, then increased by 0.47% to $424000.0 in 2023.
  • Per Business Quant, the three most recent readings for HRMY's Amortization of Deferred Charges are $424000.0 (Q2 2023), $416000.0 (Q1 2023), and $422000.0 (Q4 2022).